Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ulrika S H Simonsson

Showing results (61-70 of 108) with videos related to

Pageof 11
Sort By:
Antiviral Therapy|January 24, 2012
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected childrenChao Zhang, Helen McIlleron, Yuan Ren, et al.
Scientific Reports|September 28, 2023
Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19Rob C van Wijk, Laurynas Mockeliunas, Gerben van den Hoogen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 4, 2011
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patientsDaniel Röshammar, Ulrika S H Simonsson, Håkan Ekvall, et al.
Journal of Clinical Pharmacology|September 22, 2006
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adultsOle Osterberg, Radojka M Savic, Mats O Karlsson, et al.
Fundamental & Clinical Pharmacology|May 25, 2007
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjectsSara Asimus, Doaa Elsherbiny, Trinh N Hai, et al.
Frontiers in Pharmacology|December 26, 2022
Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of <i>in vitro</i>, <i>in vivo</i> methodologies and human studiesJan-Willem C Alffenaar, Jurriaan E M de Steenwinkel, Andreas H Diacon, et al.
Clinical Pharmacology and Therapeutics|June 28, 2017
A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin DosesRobin J Svensson, Rob E Aarnoutse, Andreas H Diacon, et al.
Clinical Pharmacology and Therapeutics|April 28, 2018
Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With RifampicinSebastian G Wicha, Oskar Clewe, Robin J Svensson, et al.
Antimicrobial Agents and Chemotherapy|July 31, 2019
Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid CultureRobin J Svensson, Wilber Sabiiti, Gibson S Kibiki, et al.
Pharmaceutics|April 23, 2022
Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant TuberculosisLaurynas Mockeliunas, Lina Keutzer, Marieke G G Sturkenboom, et al.
Pageof 11

Showing results (61-70 of 108) with videos related to

Sort By:
Pageof 11
Antiviral Therapy|January 24, 2012
Population pharmacokinetics of lopinavir and ritonavir in combination with rifampicin-based antitubercular treatment in HIV-infected childrenChao Zhang, Helen McIlleron, Yuan Ren, et al.
Scientific Reports|September 28, 2023
Reproducibility in pharmacometrics applied in a phase III trial of BCG-vaccination for COVID-19Rob C van Wijk, Laurynas Mockeliunas, Gerben van den Hoogen, et al.
Journal of Pharmacokinetics and Pharmacodynamics|October 4, 2011
Non-linear mixed effects modeling of antiretroviral drug response after administration of lopinavir, atazanavir and efavirenz containing regimens to treatment-naïve HIV-1 infected patientsDaniel Röshammar, Ulrika S H Simonsson, Håkan Ekvall, et al.
Journal of Clinical Pharmacology|September 22, 2006
Pharmacokinetics of desmopressin administrated as an oral lyophilisate dosage form in children with primary nocturnal enuresis and healthy adultsOle Osterberg, Radojka M Savic, Mats O Karlsson, et al.
Fundamental & Clinical Pharmacology|May 25, 2007
Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjectsSara Asimus, Doaa Elsherbiny, Trinh N Hai, et al.
Frontiers in Pharmacology|December 26, 2022
Pharmacokinetics and pharmacodynamics of anti-tuberculosis drugs: An evaluation of <i>in vitro</i>, <i>in vivo</i> methodologies and human studiesJan-Willem C Alffenaar, Jurriaan E M de Steenwinkel, Andreas H Diacon, et al.
Clinical Pharmacology and Therapeutics|June 28, 2017
A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin DosesRobin J Svensson, Rob E Aarnoutse, Andreas H Diacon, et al.
Clinical Pharmacology and Therapeutics|April 28, 2018
Forecasting Clinical Dose-Response From Preclinical Studies in Tuberculosis Research: Translational Predictions With RifampicinSebastian G Wicha, Oskar Clewe, Robin J Svensson, et al.
Antimicrobial Agents and Chemotherapy|July 31, 2019
Model-Based Relationship between the Molecular Bacterial Load Assay and Time to Positivity in Liquid CultureRobin J Svensson, Wilber Sabiiti, Gibson S Kibiki, et al.
Pharmaceutics|April 23, 2022
Model-Informed Precision Dosing of Linezolid in Patients with Drug-Resistant TuberculosisLaurynas Mockeliunas, Lina Keutzer, Marieke G G Sturkenboom, et al.
Pageof 11